Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes

Primary Hypothesis: The 12-week henagliflozin taking could induce significantly higher weight loss in obese subjects without diabetes, compared to diet-exercise therapy. Assessment time points: Baseline: prior to taking henagliflozin or diet-exercise therapy V1: 4 weeks following the henagliflozin taking or diet-exercise therapy V2: 4 weeks following V1 V3: 4 weeks following V2 Specific Aims 1: To examine and compare the weight loss, assessed by weight, waist circumference, hip circumference and BMI, after 12-week henagliflozin taking or diet-exercise therapy in obese without diabetes. Specific Aims 2: To examine and compare the change of glucose level after 12-week henagliflozin taking or diet-exercise therapy in obese without diabetes. Secondary Hypothesis 1: The 24-week henagliflozin taking could siginificantly improve the glucose control in obese subjects with pre-diabetes, compared to diet-exercise therapy. Assessment time points: Baseline: prior to taking henagliflozin or diet-exercise therapy V4: 12 weeks following V3 Specific Aims: To examine and compare the change of glucose level, assessed by fasting plasma glucose (FPG), postprandial plasma glucose (PPG), HbA1c, insulin levels, after 24-week henagliflozin taking or diet-exercise therapy.